Monteith, B. E., Venner, C. P., Cheung, M. C., Pater, J., Shepherd, L., Richardson, H., Reece, D., Gul, E., Lalancette, M., Castonguay, V., Kukreti, V., Tiedemann, R., Phua, C., Bhella, S., Dudebout, J., Sherry, M., Yen, H., Chen, B. E., & Hay, A. E. (2021). a descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. European journal of haematology, 107, 333–342. http://access.bl.uk/ark:/81055/vdc_100136729070.0x000045